Stockscreener 앱 받기
144.40
0.56%
-0.81
시간 외 거래:
144.40
전일 마감가:
$145.21
열려 있는:
$146.52
하루 거래량:
3.83M
Relative Volume:
0.54
시가총액:
$179.26B
수익:
$29.45B
순이익/손실:
$8.51B
주가수익비율:
21.29
EPS:
6.7823
순현금흐름:
$9.46B
1주 성능:
-2.80%
1개월 성능:
-7.00%
6개월 성능:
+28.63%
1년 성능:
+28.63%
1일 변동 폭
$143.27
$146.71
1주일 범위
$142.68
$149.30
52주 변동 폭
$93.37
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
144.40 | 180.27B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
930.35 | 883.28B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
238.11 | 586.06B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.76 | 391.56B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
191.29 | 297.77B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.85 | 295.52B | 54.72B | 14.02B | 15.32B | 7.1855 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences ASCENT-04 regimen gains Category 1 status in updated NCCN guidelines - Traders Union
Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast Cancer - PRWeb
Cantor Fitzgerald reiterates Gilead stock rating on Yeztugo sales - Investing.com
National Bank of Canada FI Has $161.14 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push - Yahoo Finance
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth - Yahoo Finance
Fort Point Capital Partners LLC Sells 8,153 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
CSM Advisors LLC Sells 42,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bank of Nova Scotia Sells 319,843 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
Gotham Asset Management Increases Gilead Sciences Stake - National Today
Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Down 15.7% in February - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Holocene Advisors LP - MarketBeat
Gotham Asset Management LLC Has $38.40 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Crawford Investment Counsel Inc. Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades - Insider Monkey
Capitolis Liquid Global Markets LLC Invests $40.40 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Calydon Capital Has $7.34 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Chevy Chase Trust Holdings LLC Has $70.93 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
California Public Employees Retirement System Has $447.80 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
BNP Paribas Has $7.71 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Ameriprise Financial Inc. Buys 400,002 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Alliancebernstein L.P. Sells 258,213 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Wellington Management Group LLP Has $2.84 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Prudential PLC - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Dodge & Cox Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded at Wall Street Zen - MarketBeat
Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - Stock Traders Daily
'Manufacturing is access': How Gilead's early production moves set PrEP med Yeztugo up for success - Fierce Pharma
Analysts Set Expectations for Gilead Sciences Q1 Earnings - MarketBeat
Martingale Asset Management L P Decreases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Invesco Ltd. Purchases 1,618,453 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
The Zacks Analyst Blog Oracle, T-Mobile, Gilead, and C&F Financial - Yahoo Finance Singapore
How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story - finance.yahoo.com
[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity - Stock Titan
Stock Traders Purchase Large Volume of Call Options on Gilead Sciences (NASDAQ:GILD) - MarketBeat
HIV prevention efforts amplified through music at SXSW, Gilead Sciences asserts - Traders Union
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum And Mixed Fair Value Signals - simplywall.st
Gilead Sciences, Inc. $GILD Stake Boosted by SageView Advisory Group LLC - MarketBeat
Franklin Resources Inc. Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Bokf Na Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (NASDAQ:GILD) Institutional Focus Rises In Nasdaq 100 Index - Kalkine Media
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
Gilead Sciences at Barclays Conference: Strategic Growth and Diversification - Investing.com
News | British Land and Royal London sign Gilead at Euston development - CoStar
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.16%
자본화:
|
볼륨(24시간):